NCT00261807View on ClinicalTrials.gov

Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Fasciitis, NecrotizingSevere Necrotizing Skin and Soft Tissue InfectionsFournier's Gangrene
Interventions
DRUG

Daptomycin 6mg/kg/day

Trial Locations (1)

21201

R Adams Cowley Shock Trauma Center, U. of Maryland Medical Center, Baltimore

All Listed Sponsors
collaborator

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

lead

University of Maryland, Baltimore

OTHER

NCT00261807 - Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections | Biotech Hunter | Biotech Hunter